Fingerprint
Dive into the research topics of 'A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically